Liu, X., Chong, Y., Tu, Y., Liu, N., Yue, C., Qi, Z., . . . Yu, R. (2016). CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways. J Hematol Oncol.
Citación estilo ChicagoLiu, Xuejiao, et al. "CRM1/XPO1 Is Associated With Clinical Outcome in Glioma and Represents a Therapeutic Target By Perturbing Multiple Core Pathways." J Hematol Oncol 2016.
Cita MLALiu, Xuejiao, et al. "CRM1/XPO1 Is Associated With Clinical Outcome in Glioma and Represents a Therapeutic Target By Perturbing Multiple Core Pathways." J Hematol Oncol 2016.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.